Clinical Trials

Multiple clinical trials are currently evaluating KL001 for the therapeutic management of severe to moderately severe hemophilia B without inhibitors. Sponsored by academic and medical institutions including Zhejiang University and the Affiliated Hospital of Guangdong Medical University, these early phase I studies aim to assess the preliminary safety, efficacy, and dose-finding profiles of the molecule. According to available records, the recruitment status for these investigations is currently categorized as unknown.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT06125756 UNKNOWN
Hemophilia B Without Inhibitor
Affiliated Hospital of Guangdong Medical University
2023-12-20 EARLY_PHASE1
NCT06119659 UNKNOWN
Hemophilia B Without Inhibitor
Zhejiang University
2023-11-20 EARLY_PHASE1

(data from https://clinicaltrials.gov, updated on 2023-11-09)

Check the KL001 product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

KL001 functions as a small-molecule stabilizer that specifically binds to cryptochrome (CRY), preventing its ubiquitin-dependent degradation and thereby lengthening the cellular circadian period. By stabilizing circadian rhythm machinery and modulating downstream pathway signaling, KL001 is currently being investigated for its therapeutic relevance in early-phase clinical studies targeting hemophilia B without inhibitors.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.